Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Unknown 2Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 3NIH 1

Study Type

Interventional 4Expanded_access 2

Sponsor

Cancer Type

Other 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Prostate Cancer Recurrent 1Ototoxicity 1Mucositis 1Glioblastoma 1Dermatitis 1Anus Neoplasms 1

Interventions

Cyclophosphamide 3155Cisplatin 3151Carboplatin 2929Paclitaxel 2671Radiotherapy 2643Gemcitabine 2544pembrolizumab 2324Docetaxel 2154Bevacizumab 2126Fluorouracil 1819Capecitabine 1780Oxaliplatin 1709Dexamethasone 1589Nivolumab 1516Doxorubicin 1477Rituximab 1453Etoposide 1341Magnetic Resonance Spectroscopy 1261Irinotecan 1232Leucovorin 1212Cytarabine 1123Pemetrexed 1060Drug Therapy 1060fludarabine 1044Vincristine 956Specimen Handling 928Prednisone 924Cetuximab 919Lenalidomide 916Trastuzumab 897

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × tempol × Clear all
NCT03480971 2024-11-20

Treatment of Radiation and Cisplatin Induced Toxicities with Tempol

Matrix Biomed, Inc.

Phase 2 Recruiting
120 enrolled
Other

Ototoxicity, Mucositis

NCT01324141 2021-11-23

Topical MTS-01 for Dermatitis During Radiation and Chemotherapy for Anal Cancer

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
6 enrolled 28 charts
Gastrointestinal

Anus Neoplasms, Dermatitis

NCT04876755 2021-05-06

MBM-02 (Tempol) for the Treatment of Biochemical Recurrent Prostate Cancer

Matrix Biomed, Inc.

Phase 2 Unknown
55 enrolled
Genitourinary

Prostate Cancer Recurrent

NCT04874506 2021-05-05

MBM-02 (Tempol) for the Treatment of Glioblastoma Multiforme (GBM)

Matrix Biomed, Inc.

Phase 2 Unknown
55 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡